Leap Therapeutics Shifts Focus to Colorectal Cancer After Mixed Phase 2b Trial Results

January 30, 2025

Tvardi Therapeutics Reports Phase 2 Failure for IPF Drug Candidate TTI-101

October 17, 2025

Life Sciences Voice Top Five Newsletter

August 21, 2023

Must Read

Lilly Adds $4.5 Billion to Indiana Manufacturing Expansion, Total U.S. Commitments Exceed $50 Billion

May 9, 2026

Madrigal Licenses ARO-PNPLA3 from Arrowhead in Deal Worth Up to $1 Billion

May 9, 2026

Viridian’s Tepezza Competitor Hits Another Phase 3 Win; Door Opens For FDA Nod

May 8, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Kailera Details Nasdaq IPO Plans to Raise Up to $528.5 Million for Obesity Drug Development

Avalyn Files for IPO to Fund Late-Stage Development of Inhaled Lung Disease Therapies

Merck Pays $20 Million Upfront to Access Quotient’s Somatic Genomics Platform for IBD Research

Merck Gets $700M Funding From Blackstone For Cancer Therapy R&D

Myqorzo from Cytokinetics wins historic cardiomyopathy trial

Gedatolisib from Celcuity outperforms Piqray from Novartis in phase 3 research

Takeda Reports Phase 2/3 Data Showing TAK-881 Comparable to HyQvia in Primary Immunodeficiency Disease

In a late-stage trial, Intellia’s gene treatment for rare condition reduces swelling attacks

Madrigal Licenses ARO-PNPLA3 from Arrowhead in Deal Worth Up to $1 Billion

Amgen Adds $300 Million to Puerto Rico Expansion, Bringing U.S. Investment Commitments Near $2 Billion

Chiesi to Acquire KalVista for $1.9 Billion, Adding Oral HAE Therapy Ekterly

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances

PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm

Is Green Biotech the Future of Sustainable Drug Development?

Top 10 High-Impact Careers Defining the Future of Life Sciences

Top 10 Pharma Companies Leading Innovation in Drug Development (2026)

Top 10 Breakthrough Therapies Shaping the Future of Medicine (2026)

Clinical

Apellis and Novartis both target rare kidney diseases with new drugs

Editor Picks

Leap Therapeutics Shifts Focus to Colorectal Cancer After Mixed Phase 2b Trial Results

Tvardi Therapeutics Reports Phase 2 Failure for IPF Drug Candidate TTI-101

Life Sciences Voice Top Five Newsletter

Must Read

Lilly Adds $4.5 Billion to Indiana Manufacturing Expansion, Total U.S. Commitments Exceed $50 Billion

Madrigal Licenses ARO-PNPLA3 from Arrowhead in Deal Worth Up to $1 Billion

Viridian’s Tepezza Competitor Hits Another Phase 3 Win; Door Opens For FDA Nod

Hot Topics

About Us

Follow Us